Pediatric Atopic Dermatitis

Alphyn Biologics reported positive results for topical AB-101a in a phase 2a clinical trial in pediatric patients with mild to moderate atopic dermatitis.

The European Medicines Agency has recommended extending Dupixent approval to treat severe atopic dermatitis in children aged 6 months to 5 years in the European Union, Regeneron Pharmaceuticals and Sanofi announced in a press release.

Children with atopic dermatitis, but not those with psoriasis, were likely to be absent from school at least 15 days a year due to their condition, according to a study.

Delgocitinib ointment was associated with improved efficacy over placebo in pediatric patients with moderate atopic dermatitis through 56 weeks of follow-up, according to a study.

Methotrexate and azathioprine yielded similar risk-benefit ratios as first-line therapy for children with severe atopic dermatitis, according to a study.

Findings from a phase 3 clinical trial support the use of weight-based Dupixent dosing in adolescents with moderate to severe atopic dermatitis.

Amy S. Paller, MD, of Northwestern University Feinberg School of Medicine, discussed the importance of better awareness of atopic dermatitis, such as its symptoms and medication choices, among affected individuals and those around them.

In this video, Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair in The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, discusses how dermatologists can differentiate atopic dermatitis from other skin conditions that may mimic its symptoms.

Amy S. Paller, MD, of Northwestern University Feinberg School of Medicine, discussed recent developments in atopic dermatitis and what’s coming up in the pipeline.

In this video, Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair in The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, discusses recent developments in the treatment of atopic dermatitis.